Efficacy and biomarker analysis of nivolumab plus gemcitabine and cisplatin in patients with unresectable or metastatic biliary tract cancers: results from a phase II study

Efficacy and biomarker analysis of nivolumab plus gemcitabine and cisplatin in patients with unresectable or metastatic biliary tract cancers: results from a phase II study

Background The prognosis of patients with unresectable or metastatic biliary tract cancer (BTC) is unacceptably low. This study aimed to determine the efficacy, safety and predictive biomarkers of the immune checkpoint inhibitor nivolumab in combination with chemotherapy in advanced BTCs.Methods In...

Full description

Saved in:

Bibliographic Details
Main Authors:	Yang Liu, Xiang Li, Qian Mei, Weidong Han, Liang Dong, Qingming Yang, Jiejie Liu, Kaichao Feng, Yongtian Zhao, Zhikun Zhao
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2020-05-01
Series:	Journal for ImmunoTherapy of Cancer
Online Access:	https://jitc.bmj.com/content/8/1/e000367.full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Gemcitabine Cisplatin and Durvalumab Experience in Advanced Biliary Tract Cancers: A Real-World, Multicentric Data From India
by: Vamshi Krishna Muddu, et al.
Published: (2024-12-01)

Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial
by: Jian Wang, et al.
Published: (2020-10-01)

Conversion therapy for unresectable intrahepatic cholangiocarcinoma using gemcitabine plus S-1 combined with PD-1 inhibitors: a case report
by: Shuangying Zhao, et al.
Published: (2025-01-01)

Cost-effectiveness of nivolumab combined with chemotherapy as a first-line therapy for patients with unresectable or metastatic urothelial carcinoma
by: Jingwen Lin, et al.
Published: (2024-12-01)

Re-exposition to ipilimumab plus nivolumab in metastatic Merkel cell carcinoma
by: Valerie Glutsch, et al.
Published: (2024-12-01)

Nab-Paclitaxel plus gemcitabine in patients with metastatic pancreatic adenocarcinoma: experience of use
by: Elena Ferris Villanueva, et al.
Published: (2015-02-01)

Phase I Trial of Upamostat Combined With Gemcitabine in Locally Unresectable or Metastatic Pancreatic Cancer: Safety and Preliminary Efficacy Assessment
by: Xiuping Lai, et al.
Published: (2025-01-01)

Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study
by: Arun Singh, et al.
Published: (2020-05-01)

Matters arising: On the cost-effectiveness for the Italian National Health Service of nab-paclitaxel plus gemcitabine vs gemcitabine alone in metastatic pancreatic cancer
by: Carlo Lazzaro
Published: (2024-12-01)

Correction: Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study
Published: (2020-10-01)

Toxic epidermal necrolysis induced by nivolumab therapy for unresectable intraperitoneal cancer
by: Hiroyoshi Nozaki, et al.
Published: (2025-01-01)

Addition of SHR-1701 to first-line capecitabine and oxaliplatin (XELOX) plus bevacizumab for unresectable metastatic colorectal cancer
by: Miao-Zhen Qiu, et al.
Published: (2024-12-01)

Modification of gemcitabine with oxaliplatin in China for unresectable gallbladder cancer: a cost-effectiveness analysis
by: Zhaoyan Chen, et al.
Published: (2024-12-01)

Pathologic Response Rates of Gemcitabine/Cisplatin versus Methotrexate/Vinblastine/Adriamycin/Cisplatin Neoadjuvant Chemotherapy for Muscle Invasive Urothelial Bladder Cancer
by: Franklin C. Lee, et al.
Published: (2013-01-01)

Atezolizumab plus bevacizumab in patients with unresectable or metastatic mucosal melanoma: 3‐year survival update and multi‐omics analysis
by: Jie Dai, et al.
Published: (2025-01-01)

A non-inferiority, phase III trial of gemcitabine plus capecitabine gemcitabine plus carboplatin as first-line therapy and tumor-infiltrating lymphocytes as a prognostic biomarker in patients with advanced triple-negative breast cancer
by: Xiaodong Liu, et al.
Published: (2024-12-01)

Alternating modified CAPOX/CAPIRI plus bevacizumab in untreated unresectable metastatic colorectal cancer: a phase 2 trial
by: Sheng Li, et al.
Published: (2024-12-01)

Durvalumab Plus Chemotherapy for Advanced Biliary Tract Cancer Treatment: Insights from the TOPAZ-1 Trial
by: Ralph Fritsch
Published: (2024-10-01)

A phase 3 study of the efficacy, safety, and pharmacokinetics profile of subcutaneous vs intravenous nivolumab + relatlimab fixed-dose combination in previously untreated metastatic or unresectable melanoma (RELATIVITY-127)
by: G.V. Long, et al.
Published: (2024-01-01)

Long-Term Temporal Trends of Real-World Healthcare Costs Associated with Nivolumab Plus Ipilimumab and Pembrolizumab Plus Axitinib as First-Line Treatment for Advanced or Metastatic Renal Cell Carcinoma
by: Ella Xiaoyan Du, et al.
Published: (2024-08-01)

Real-World Oncological Outcomes of Nivolumab Plus Ipilimumab in Advanced or Metastatic Renal Cell Carcinoma: A Multicenter, Retrospective Cohort Study in Japan
by: Tomoki Taniguchi, et al.
Published: (2024-12-01)

Electrospun nanofibrous mats loaded with gemcitabine and cisplatin suppress bladder tumor growth by improving the tumor immune microenvironment
by: Jing Wang, et al.
Published: (2024-03-01)

Acute Left Internal Carotid Artery and Right Popliteal Artery Occlusion Related to Cisplatin-Gemcitabine Based Chemotherapy
by: Saman Zafar, et al.
Published: (2018-01-01)

A prospective, open-label, interventional study protocol to evaluate treatment efficacy of nivolumab based on serum-soluble PD-L1 concentration for patients with metastatic and unresectable renal cell carcinoma
by: Yukari Bando, et al.
Published: (2019-12-01)

Case report: Systemic air embolism after percutaneous microwave ablation of an unresectable metastatic lung lesion
by: Wei Tang, et al.
Published: (2024-11-01)

Nivolumab and Ipilimumab Combination Immunotherapy for Patients with Metastatic Collecting Duct Carcinoma
by: Tetsuya Danno, et al.
Published: (2021-01-01)

Long Complete Remission Achieved with the Combination Therapy of Cisplatin and Gemcitabine in a Patient with Aggressive Natural Killer Cell Leukemia
by: Justin LaPorte, et al.
Published: (2015-01-01)

The anti-PD-L1/CTLA-4 bispecific antibody KN046 plus lenvatinib in advanced unresectable or metastatic hepatocellular carcinoma: a phase II trial
by: Da Xu, et al.
Published: (2025-02-01)

Pembrolizumab Therapy Leading to Complete Remission for Recurrence of Pulmonary Metastases after their Resection and Radical Cystectomy following Gemcitabine and Cisplatin Therapy
by: Kyohei Ishida, et al.
Published: (2024-01-01)

Pre-radiation Nivolumab plus ipilimumab in patients with newly diagnosed high-grade gliomas
by: Santosh Kesari, et al.
Published: (2024-12-01)

Circulating cytokine associations with clinical outcomes in melanoma patients treated with combination nivolumab plus ipilimumab
by: Jiajia Chen, et al.
Published: (2025-12-01)

Gallbladder Agenesis without Additional Biliary Tracts Abnormality
by: Seyed Mostafa Meshkati Yazd, et al.
Published: (2022-01-01)

Phase I study of pembrolizumab in combination with ibrutinib for the treatment of unresectable or metastatic melanoma
by: Yuan Yao, et al.
Published: (2025-02-01)

Effectiveness and safety of atezolizumab, nivolumab and pembrolizumab in metastatic non-small cell lung cancer
by: Amparo Burgos-San José, et al.
Published: (2021-05-01)

Efficacy and safety of nivolumab plus ipilimumab in gastrointestinal cancers: a systematic review and meta-analysis
by: Bowen Dai, et al.
Published: (2025-01-01)

PD(L)1 Inhibitors Plus Lenvatinib Vs Atezolizumab Plus Bevacizumab Combined With HAIC for Unresectable HCC: A Propensity Score Matching Study
by: He Z, et al.
Published: (2025-01-01)

Fasciolopsis buski infection of the biliary tract: a case report
by: Shuai Luo, et al.
Published: (2025-01-01)

Helicobacter pylori and Biliary Tract Cancers: A Meta-Analysis
by: Soumia Cherif, et al.
Published: (2020-01-01)

METHODS OF MINIMALLY INVASIVE DECOMPRESSION OF THE BILIARY TRACT WITH MECHANICAL JAUNDICE
by: K. M. Kurbonov, et al.
Published: (2018-02-01)

Phase II trial of nab-paclitaxel plus ramucirumab in combination with nivolumab for unresectable advanced or recurrent gastric cancer after progression on first-line treatment including fluoropyrimidine, platinum, and anti-PD-1/PD-L1 antibody (PADDLE)
by: Hidekazu Hirano, et al.
Published: (2025-02-01)